Who are Riociguat Oral Product's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Verquvo, Adempas, Riociguat (Adempas), SOC: Soluble guanylate cyclase stimulator, Riociguat Pill.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/riociguat-oral-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Riociguat Oral Product — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Riociguat Oral Product (Riociguat Oral Product) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Soluble guanylate cyclase stimulator. Area: Cardiovascular.

marketed Soluble guanylate cyclase stimulator Soluble guanylate cyclase (sGC) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Riociguat Oral Product (Riociguat Oral Product) — University of Calgary. Riociguat is a soluble guanylate cyclase stimulator that increases cyclic GMP levels to promote vasodilation and reduce pulmonary vascular resistance.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Riociguat Oral Product TARGET	Riociguat Oral Product	University of Calgary	marketed	Soluble guanylate cyclase stimulator	Soluble guanylate cyclase (sGC)
Verquvo	VERICIGUAT	Merck & Co.	marketed	Soluble Guanylate Cyclase Stimulator [EPC]	Guanylate cyclase soluble subunit beta-1	2021-01-01
Adempas	RIOCIGUAT	Bayer	marketed	Soluble Guanylate Cyclase Stimulator [EPC]	Guanylate cyclase soluble subunit beta-1	2013-01-01
Riociguat (Adempas)	Riociguat (Adempas)	Chinese University of Hong Kong	marketed	Soluble guanylate cyclase stimulator	Soluble guanylate cyclase (sGC)
SOC: Soluble guanylate cyclase stimulator	SOC: Soluble guanylate cyclase stimulator	Actelion	phase 3	Soluble guanylate cyclase stimulator	Soluble guanylate cyclase (sGC)
Riociguat Pill	Riociguat Pill	University of Arizona	phase 3	Soluble guanylate cyclase stimulator	Soluble guanylate cyclase (sGC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Soluble guanylate cyclase stimulator class)

Actelion · 1 drug in this class
Chinese University of Hong Kong · 1 drug in this class
University of Arizona · 1 drug in this class
University of Calgary · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Riociguat Oral Product — Competitive Intelligence Brief. https://druglandscape.com/ci/riociguat-oral-product. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab